56844-12-3

Basic information

• Product Name: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE
• Synonyms: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE;6-broMo-4-chlorothieno[2
• CAS NO: 56844-12-3
• Molecular Formula: C₆H₂BrClN₂S
• Molecular Weight: 249.51
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 56844-12-3.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 345.5 °C at 760 mmHg
• Flash Point: 162.7 °C
• Appearance: /
• Density: 1.955 g/cm³
• Vapor Pressure: 0.000123mmHg at 25°C
• Refractive Index: 1.735
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.34±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(56844-12-3)
• EPA Substance Registry System: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(56844-12-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 56844-12-3(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-chlorothieno[2,3-d]pyrimidine is a chemical compound with the molecular formula C6H2BrClN2S. It is a heterocyclic compound that contains a thieno[2,3-d]pyrimidine ring system with bromine and chlorine substituents at the 6 and 4 positions, respectively. 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE has potential applications in pharmaceutical and agrochemical industries as a building block for the synthesis of various biologically active compounds. It is also of interest in organic synthesis due to its unique structural features and reactivity. The compound is typically synthesized through a series of chemical reactions and can be used as a reagent in various chemical transformations.

InChI:InChI=1/C6H2BrClN2S/c7-4-1-3-5(8)9-2-10-6(3)11-4/h1-2H

Upstream product

• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4(3H)-one 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(3H)one 
• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4-ol 
• 14080-59-2 4-chlorothieno[2,3-d]pyrimidine 
• 109-72-8 n-butyllithium 
• 4651-81-4 Methyl 2-aminothiophene-3-carboxylate 
• 14080-50-3 4-hydroxythieno[2,3-d]pyrimidine 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(1H)-one 

Downstream Products

• 814918-95-1 5-bromo-4-chlorothieno[2,3-d]pyrimidine 
• 552294-86-7 6-bromo-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)thieno[2,3-d]pyrimidin-4-amine 
• 1217309-73-3 4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine 
• 1217309-75-5 2-(4-chlorophenoxy)-1-(4-(6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethanone 
• 1245320-31-3 N-(3-chloro-4-fluorophenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-amine 
• 885229-27-6 4-chloro-5-iodo-thieno[2,3-d]pyrimidine 
• 1370338-71-8 4-chloro-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1370338-31-0 2-methyl-5-(5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-ylthio)-1,3,4-oxadiazole 
• 1388892-46-3 4-N-[6-cycIopropylthieno[2,3-d]pyrimidin-4-yl]-1-N,1-N-dimethylcyclohexane-1,4-diamine 
• 1407964-94-6 (R)-6-(4-methoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine 
• 1408055-32-2 (R)-N-(1-phenylethyl)-6-(4-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine 
• 1408055-34-4 (R)-2-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)phenol 
• 1408055-35-5 (R)-6-mesityl-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine 
• 1408055-36-6 (R)-N-(1-phenylethyl)-6-(2,4,6-tri-isopropylphenyl)thieno[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

One-pot synthesis of α-aminophosphonates via a cascade sequence of allylamine isomerization/hydrophosphonylation

A Rh/Ni-catalyzed cascade sequence of allylamine isomerization and hydrophosphonylation to synthesize α-aminophosphonates has been disclosed. The reaction, which not only allows the generation of widespread valuable α-aminophosphonates under simple system

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt- Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, myocardial infarction, neurodegeneration, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, more specifically cancers of the breast, colon, pancreas and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.